Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can you imagine the cost burden SOLI would have to take on to take the SEC to court, and all for what? The SEC to say sorry and re-list? How long would it take for the lawsuit to complete?
I'm sure after discussing with their SEC attorney, it was advised to just file a new 211.
Obviously being behind on their financials doesn't help, but the SEC isn't going to do anything more than what they already did, provide a no further action letter.
Elvis, take a step back, read replies thoroughly and think before posting.
SOLI got caught up in the SEC's sweep of OTC stocks mentioning COVID. CareClix filed an 8K explaining exactly what they were messaging in their PR and even provided the name of the laboratory which would be sending out the test kits. It needs to be brought up again that SOLI never claimed to be selling test kits. Compare that to the numerous companies who claimed to have millions of face masks, and other COVID killer products already stocked up and ready for sale.
Since this sweep of suspensions, a handful of insiders across multiple companies were sued for their blatant lies during the early days of COVID, while SOLI received a no further action required.
It'll be a 10K not quarterly, so they have until end of January.
It would be nice if they post early in time for that Jan conference, but if they do post early, we'll be waiting 4 months until the next Q's due date.
Either way, it's a patience play. It seems like they are growing very nicely, so everything should work out in time.
Too much momentum out there, everyone would rather chase turds than purchase some KAVL.
Oh well, when things are quiet we may get some more eyes, either way, value is here, and will only continue to grow.
Maybe that conference in Jan will shed some long term eyes on us.
Trading the OTCs for 15 years I've learned that anything and everything can happen.
Regardless of what happens though, I am a buyer lower and a seller much higher, anything that happens in between is just noise.
We have a winner, is it a winner this week, next week, next month? I can't say, but we have a winner, that is one thing I do know.
Have a goodnight
Looking forward to it!
This one has been a roller coaster for those who've held the last few months, but its also given some great buying opportunities.
If you say so, but we know how wrong you've been so far.
Did you notice even with etrade not allowing buying on CE stocks, SOLI continues to do more than 20k average volume?
Nice stack sello, I hope we all see this work out in the short term, if not, whatever we can just hold a bit longer haha. LT Capital gains pls!
I don't wish wish. But if it does I'll be ready to pick up more.
I've been here since the 1A was filed, so a bit longer than you. I've picked up plenty of shares since my first .04 buys. There is clearly value here, but when that value is exposed, no one can say. It'll happen when it happens. 005 has the same chance as hitting as .04 until something new is given to us.
Been down there 3 times in the last 3 months, so because you're invested now it won't go down that low? lol, okay.
It might not go down that low, it took less volume to take us near .02 so as someone else said, looks like the float is getting locked up.
I don't believe so, feel free to prove that wrong though.
Did you read the whole sentence or stop half way? Typical, here is what happened Elvis...
CareClix got caught up in an SEC sweep because it mentioned Covid back when no one knew what was going on. Did you know the lab they were working with to provide testing kits is actually one of two with pending contracts with the state of Virginia? That was as of May, I haven't dug in too much more because that's enough for me to trust the legitimacy of the source.
Virginia is in the process of finalizing contracts with private labs to expand COVID-19 testing in Virginia.
As of Monday, the other two labs -- North Carolina-based Mako Medical and Virginia-based Next Bio-Research Services LLC, also called Next Molecular Analytics, say their contracts are still pending
https://vpm.org/news/articles/13312/virginia-finalizing-private-lab-contracts-to-expand-covid-19-testing
It's a document provided to the state with business name, address and directors/officers.
Well on August 28th CareClix Inc sent in their Annual report to the state of Virginia, with Korangy still as CEO, and their address the same as SOLI's.
Additionally, the website has been updated multiple times and CareClix Inc still is a subsidiary of SOLI.
So seems to me the acquisition wasn't undone.
I own a decent amount and bought more last time we were down in the 005s.
Chart wise though it's looking tired, BUT, you really never know. We could get some strong buying, gap over .015 and never look back. Or we may drop down before moving back up. Updates from the company can help.
Still long, just unsure of timeline.
This is straight from their 8K after the SEC's suspension:
CareClix does not sell, promote, nor have we ever sold COVID-19 kits. We do not make any money from testing kits. We make money by providing patients with telemedicine access to doctors and also providing our platform to a growing customer list of doctors, hospitals, clinics and employer groups.
Chart was looking good, but it hasn't been able to hold over .015.
Short term looks like a retest of the 50 day and maybe even low 005s.
Seems perfectly legit that CareClix was utilizing Next for testing.
https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/notifications-and-emergency-use-authorizations-faqs-testing-sars-cov-2
A: No. FDA does not expect any notification or EUA request from laboratories that are performing testing using EUA-authorized test kits purchased from commercial manufacturers or their distributors. Facilities performing COVID-19 testing must be certified under the Clinical Laboratory Improvement Amendments, or CLIA, which is administered by CMS.
https://7d2f7043-60da-494b-a021-170e20431584.filesusr.com/ugd/9b3624_17b0785d5d32473c8bf658ab902b0070.pdf
The Company initially chose to work with a lab that used an FDA approved SARS-COV-2 Coronavirus test that met the FDA Emergency Use Authorization criteria. That lab is Next Molecular Analytics, a 23-year-old laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). We relied upon the following communication from Next:
“We are pleased to announce NEXT is launching an FDA approved SARS-CoV-2 Coronavirus test for COVID-19 detection. This test meets the FDA Emergency Use Authorization (EUA) criteria as it consists of the CDC developed RT-PCR assay. This EUA allows the assay to be performed in CLIA high complexity laboratories, a classification that NEXT meets. NEXT has worked tirelessly over the past few weeks to obtain the assays and validate so that we may perform testing for those patients that physicians feel meet the requirements for testing.”
Also, Melissa Russell - Director of Clinical Business Operations said, “NEXT [Molecular] will be responsible for sending kits to patients overnight and for providing materials to overnight those samples back to our facility for testing.”
Niraj bought $50,000 worth of shares this week.
Eric bought $22,000 worth of shares this week.
Despite receiving shares for compensation, and owning the 204M shares in the control block under Kavl holdings, they still bought $72k worth of stock in the open market.
Seems like they know exactly what we feel about the share price on this board; that it's undervalued.
It's on the grays due to being a shady company or that it got caught up in the SEC sweep early on in the COVID days.
What sucks is CareClix got suspended for saying the lab they were working with had Covid test kits, but the Pfizer CEO can dump 60% of his ownership the same day they release news about having a vaccine.
Seems legit.
That doesn't make sense Elvis. The company provides a service and software, that is CareClix.
CareClix is the name of their software
CareClix Inc is the name of the company.
CareClix Inc provides the CareClix software to doctors that can provide telehealth services to their patients.
CareClix Inc provides the CareClix software to individuals who want to see a doctor through the CareClix Network. CareClix Inc bills the user $x amount, and then pays CareClix Network $x less a portion to keep for CareClix.
That's the business. That is CareClix Inc, who is owned by SOLI.
Insiders bought shares 12/8 and 12/9.
That's a vote of confidence.
lol, back to this?
You should really read the filings my friend.
"Paxonal" or Panoxol is under a different subsidiary which was sold off, or was in the process of being sold off dependent on the financials.
Additionally, CareClix or all intents and purposes is a telehealth company. They provide doctors the ability to virtually meet patients, and it allows patients to virtually see a doctor.
If your doctor isn't using CareClix or other telehealth software, then you can utilize the doctors CareClix Inc provides. CareClix Inc charges for the consultation, and then is billed for the consultation. From what I see based on the first 2 Qs of financials is that their is a built in margin between what CareClix charges and what CareClix's costs are. Thus they profit from telemedicine visits; they are a telehealth company.
I know I was expecting the 15th, but since it will be their annual, I think they get an additional 45 days, so end of January.
Was out most of the day but I grabbed more 65s. Just a matter of time here.
Ready to see what it is, been a quiet accumulation period, let's see fireworks now!
Pretty difficult to say.
I just keep looking at different metrics our competitors are currently priced at. Being on the OTC we won't have the same investors as what we see with AMWL and TDOC, but you never know. Who knows what kind of investors are waiting in the shadows for an up list back to pink or OTCQB. Who knows if institutions are involved, waiting on those financials or relisting.
I would say if they are around that $2.5-$3M month revenue range then multi-dollars shouldn't be too far off especially if we do have big $$ waiting for confirmation. That's just based on this sector being so hot.
On the flip side I'm in another OTC stock with over $55M in revenue in 2 quarters, $3.7M net income, positive cash flow and no going concern, yet it's only trading at a $100M market cap. It's a different sector, but revenues/profits don't mean as much on the OTC unfortunately.
Just makes you wonder!
No doubt there are many things that could cause higher revenue per employees but I just used the 2 biggest examples to get an idea of what they are doing.
If we are profitable chances are the revenue per employee is higher and would have a higher share price.
But keep in mind, we weren't at 60 employees 6 months ago, so the financials that come out for 2019/2020 might not match the revenue number I calculated.
We just need to see what they have and we should soon.
It will be interesting to see how they move forward. If they no longer are utilizing the NOL do they try to stay hidden still or do they just accept that they are a public company with a duty to their shareholders.
I got to thinking tonight.
All us longs have faith that SOLI is CareClix. We all believe that CareClix is a fast growing telemedicine company, and we believe this based on their LinkedIn, the filings, business registration, the multiple news articles we read and all the deals/agreements have been inked since last year (and who knows how many we haven't seen!). Due to our belief, we all feel that SOLI is extremely undervalued based on the legitimate entity (CareClix) under our umbrella.
THUS, we should start to look at realistic valuations and maybe get an idea of what these financials are going to look like. I'd love $50, but I don't think that is in the cards for a very long time. (Sorry guys!)
Revenue Per Employee on LinkedIn*:
TDOC - $289M revenue last quarter / 2,852 Employees = $101,332
AMWL - $62M revenue last quarter / 475 Employees = $131,789
CareClix 64 Employees * Average revenue/employee for competitors = $7.5M estimated quarterly revenue.
Market Valuation Multiple of Revenue:**:
TDOC - $29.5B / $289M = 102X
AMWL - $6.6B / $62.6M = 105X
CareClix $7.5M (From above) * 103.5 (Average TDOC/AMWL multiple) = $772M
$772M Market Cap
223M O/S
$3.46 per share
That is a 1000% upside potential and this is why I continue to hold and buy more. SOLI, from everything I've seen from this board, and what I've dug up, tells me these valuations aren't out of this world.
CareClix is real, they aren't a serial news releaser, diluting company that has no real business strategy other than selling shares. These guys have a real business, and even if you don't like management, there have been plenty of other jerks, idiots, psychopaths, etc that have become multi-millionaires if not billionaires, so why can't this team?
Why can't CareClix become the next Telemed star? SOLI can come off the greys, change ticker, change name, and the grey past won't matter when they are generating revenue and growing their business every quarter. TSLA was under SEC investigation before and that hurt the stock, now, who doesn't want to own TSLA as it runs and runs and runs. Who said Elon will be the 2nd richest man in the world AFTER he was under SEC investigation? So again I ask you, why can't CareClix be the next Telemed All Star?
*I used LinkedIn as a source because I think it is the most up to date number publicly provided and I'd assume that TDOC, AMWL and SOLI would have a similar % of ex-employees included that no longer work there and similar % of active employees who do not use LinkedIn.
**Since TDOC/AMWL aren't profitable, it's probably easier to look at their last quarters revenue multiple to market cap.
I wonder who wrote that lol.
Anyway good write up. Looking forward to seeing updated filings.
Maybe to start a little discussion:
What kind of things could management attempt to pull off to remain in the dark? Do you think they'd go through drastic measures? I feel like they can't dilute otherwise they might lose control of the company and the airline. I also feel like they won't be able to do anything shady because now they are in the spotlight. If they sell the company for 2M it would seem shareholders can sue knowing the valuation is higher than 2M.
I cant figure out how this could go wrong and I think management has to let this reach its true valuation.
Where is this Christmas gift comment? Seen it posted a few times but don't remember coming across it.
As far as the popcorn lung, I don't think the individual was bashing, I think he was more just asking if it's related to vaping in general, or just related to those homemade cartridges.
It is interesting to see vaping getting such a bad rap. I have to assume this is similar to the way cigarettes were treated many moons ago. Is it possible the cigarette companies are lobbying against vaping so they can get into the market, gobble up market share and then they can lobby for vaping kicking out the little guys?
Either way, vaping is here to stay. Bidi Stick and Bidi Pouch are going to have a great year, especially the pouch which seems to be the hottest growing fad (per that Goldman Report). Once we have some products related to the synthetic tobacco, all bets are off.
Who knows, this might become an MJ stock too depending on what happens at the federal level.
I know I say it every post, but I really think a CBD product is going to come out next. Bidi Stick was the test, distribution channels have all been set up, as the PR said regarding Bidi Pouch, it will be hitting shelves much quicker than it took the Bidi Stick.
Last comment, I'm pretty sure all the store locations we seen numbers so far are US based. 7-Eleven has over 68,000 store locations worldwide. Having these deals in place in the US is going to help our worldwide expansion.
Obviously smoking anything isn't going to be good for the lungs but I thought I read over the years that Tobacco isn't what causes the cancers, but rather the additives.
$16 per?
I'm not sure how the deal is structured, but this could definitely increase our margins vs the bulk sales we've been doing.
I don't think we'll be doing $50M/Quarter through the website, but should definitely be helpful.
Volume has been pretty strong in this .30-.50 area. We should be churning through those excess shares pretty well now. Much better than the days of 25-50k.
Long term agreed, this is a no brainer. I might buy more because as soon as that overhanging supply of shares is gone, we'll move up very swiftly.
Good call on that margin increase. It's tough to say if we get improved terms, but that would be nice. Q2 (after the additional costs were added) margin was 11.3% vs the 13.6% in Q3.
I'm hoping that a lot of the G&A expense from Q3 is from the PMTA application. Since we don't have many employees, that shouldn't be $700k every Q. If it hangs out around that $200k number, that frees up a nice chunk of net profit.
All in all, even if Q4 isn't great, it doesn't bug me much. I just would like to get some more figures to analyze. If we can start building growth models we'll have a better idea of what KAVL is worth and can try to map our way to a higher exchange.
Where are you getting those gross profit numbers from?
At $42M revenue, I would assume $5.2-$5.7M gross profit and $3-3.3M Net income. That would be a $.01-$.012 EPS for the quarter, and $.023-.025 for the last 3 quarters.
Assuming Q1 is the same $42M, that would be $.033-.035 EPS annually. Thus, putting us at a P/E of 12x.
I don't think that the patent purchase will affect the P&L and EPS. Seems like it would just be an outlay of $$ on the cash flow statement and cash reduction accompanied by an increase of long term assets.
If it was a patent created in house, with costs relating to labor/research (R&D) then it would affect income, but this is just an asset purchase.
You know what is happening pastry.
The float increased by 13M in the last few months. Either hang on, buy more or sell. No sense making it harder than it actually is.
I disagree, we have a supply of shares overhanging us currently.
I'd be very surprised if we don't see growth quarter over quarter.